The report’s editorial board consists of 21 of the world’s leading oncologists. The report evaluated research published in review scientific journals and major scientific meetings over the year from October 2006 to September 2007, and selected those studies that significantly changed the understanding of oncology or had a significant impact on patient care, divided into six “major advances” and The research results that have significantly changed the understanding of tumor or had significant impact on patient treatment were selected into 6 “Major Advances” and 18 “Noteworthy Research”. Professor Sun Yan of the Cancer Hospital of the Chinese Academy of Medical Sciences summarized these studies, the important ones include: i. Targeted therapy: cetuximab (Erbitux) for lung cancer. It was found that for patients whose tumors express epidermal growth factor receptor (EGFR), standard chemotherapy combined with cetuximab can increase the survival rate by up to 21%. Gemcitabine (Gemzar) for pancreatic cancer. Adjuvant chemotherapy after surgical resection of the primary tumor with gemcitabine can increase disease-free survival by a factor of 1. bendamustine (Treanda) for chronic lymphocytic leukemia (CLL). bendamustine was approved by the FDA in March 2008 for the first-line treatment of CLL, and an international multicenter study found that bendamustine for CLL resulted in complete remission in 30% of patients. Bevacizumab (Avastin) for metastatic breast cancer In February 2008, the FDA approved bevacizumab in combination with paclitaxel for the first-line treatment of patients with HER2-negative metastatic breast cancer. II. Cancer prevention: Vaccines can prevent oral cancer. Studies have shown that oral cancer incidence in the United States is associated with a rise in human papillomavirus (HPV) infection, yet oral cancer incidence is not associated with a decline in HPV infection, possibly due to an increase in oral sex practices. If so, HPV vaccine could also be used to prevent oral cancer. III. Childhood cancer: Focus on childhood cancer survivors. One of the major achievements in the current fight against cancer is the increase in the number of childhood cancer survivors. But the disturbing news is that 30 years after the onset of cancer, these children have 5 to 10 times the risk of developing heart disease, due to the side effects of cancer treatment. The article also points out that a lack of oncologists has surfaced. By 2020, there will be a shortage of about 4,000 oncologists in the United States. By that time, the number of cancer patients will increase by 55% and the rate of increase of oncologists will be too slow. The article cites Vincent T DeVita, a leading American clinical oncologist and author of Principles and Practice of Cancer-Oncology (8th ed.). Doctors all over the world, especially oncologists, regard this book as a classic in oncology and refer to its views on oncology treatment as the gold standard.) Professor Vincent T DeVita (author of Cancer-Oncology Principles and Practice (8th edition), says that progress in oncology can only be incremental and it is difficult to cure all tumors in one way.